We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Karyopharm Therapeutics (KPTI) Run Higher on Strong Earnings Estimate Revisions?
Read MoreHide Full Article
Karyopharm Therapeutics Inc. (KPTI - Free Report) is a U.S. based clinical-stage pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on KPTI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Karyopharm could be a solid choice for investors.
Current Quarter Estimates for KPTI
In the past 30 days, 7 estimates have gone higher for Karyopharm while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 82 cents a share 30 days ago, to a loss of 65 cents per share today, a move of 20.7%.
Current Year Estimates for KPTI
Meanwhile, Karyopharm’s current year figures are also looking quite promising, with 8 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $3.22 per share 30 days ago to a loss of $2.86 per share today, an increase of 11.2%.
The stock has also started to move higher lately, adding 28.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Karyopharm Therapeutics (KPTI) Run Higher on Strong Earnings Estimate Revisions?
Karyopharm Therapeutics Inc. (KPTI - Free Report) is a U.S. based clinical-stage pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on KPTI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Karyopharm could be a solid choice for investors.
Current Quarter Estimates for KPTI
In the past 30 days, 7 estimates have gone higher for Karyopharm while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 82 cents a share 30 days ago, to a loss of 65 cents per share today, a move of 20.7%.
Current Year Estimates for KPTI
Meanwhile, Karyopharm’s current year figures are also looking quite promising, with 8 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $3.22 per share 30 days ago to a loss of $2.86 per share today, an increase of 11.2%.
KARYOPHARM THER Price and Consensus
KARYOPHARM THER Price and Consensus | KARYOPHARM THER Quote
Bottom Line
The stock has also started to move higher lately, adding 28.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>